Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

Core Insights - Seer, Inc. will present new findings at the 21st Annual US Human Proteome Organization (HUPO) Conference, showcasing advancements in scalable deep cellular proteomics using the Proteograph™ Product Suite [1][2] - The seminar will feature a groundbreaking study on a co-delivery therapeutic platform targeting cancer vulnerabilities, utilizing both siRNA and mRNA therapeutics [1][5] - The study aims to simultaneously inactivate tumorigenic drivers and activate lost tumor suppressors, establishing a new strategy for treating a wide range of cancers [1][5] Company Overview - Seer, Inc. is a life sciences company focused on developing transformative products for proteomics, specifically through its Proteograph™ Product Suite, which integrates engineered nanoparticles, consumables, automation instrumentation, and software for deep proteomic analysis [10] - The Proteograph workflow is designed to be efficient and user-friendly, allowing for decentralized implementation in various laboratory settings [10] Event Details - The seminar titled "Transforming Cancer Research with Deep Cellular Proteomics" will be presented by Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School on February 25, 2025 [4] - Additional presentations at the conference will highlight the role of the Proteograph Product Suite in various proteomic studies, including tissue biology and cardiometabolic dysfunction [2][6]